Sales and Marketing

Showing 15 posts of 11527 posts found.

Thomas Thorp promoted to senior director of corporate affairs at Lilly UK

November 22, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing lilly

Thomas Thorp has been promoted to senior director of corporate affairs at Lilly UK. Thorp will now lead all of …

Lucentis rival gains US approval

November 22, 2011 Research and Development, Sales and Marketing Bayer, Eylea, Lucentis, Novartis, Regeneron, Roche

A rival to Roche and Novartis’ drug Lucentis has received FDA approval for a common form of eye disease. Eylea …

Celgene opens new headquarters in UK

November 21, 2011 Research and Development, Sales and Marketing Celgene

Celgene has opened new UK headquarters in London as its haematology-based business expands. The firm says it has decided to …

Update on the planned consolidation of UK medicines legislation

November 21, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Earlier this year we reported on progress in the consolidation of the UK medicines legislation and that the Medicines and …

EMA accepts submission of Pfizer’s new arthritis drug

November 21, 2011 Research and Development, Sales and Marketing EMA, Pfizer, tofacitinib

The European Medicines Agency has accepted Pfizer’s arthritis drug tofacitinib for review.Tofacitinib is a novel, oral JAK inhibitor being studied …

Andreas Pott appointed deputy executive director of European Medicines Agency

November 21, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, Europe

The European Medicines Agency’s new executive director Guido Rasi has appointed Andreas Pott as deputy executive director. Pott’s appointment follows …

FDA pulls Roche’s Avastin for breast cancer

November 21, 2011 Research and Development, Sales and Marketing FDA, Roche, avastin

The FDA has pulled Avastin’s breast cancer licence in the US after the drug failed to prove its safety and …

Dipankar Bhattacharjee becomes vice president of Teva Northern Europe

November 21, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva

Dipankar Bhattacharjee has been promoted to vice president of UK and Teva Northern Europe. Teva said that as part of …

AstraZeneca’s thyroid cancer drug gets CHMP nod

November 21, 2011 Sales and Marketing AstraZeneca, CHMP, Caprelsa, vandetanib

AstraZeneca’s thyroid cancer pill Caprelsa has taken a step closer to European approval after being recommended by the CHMP.Caprelsa (vandetanib) …

Industry supports bid to revitalise antibiotic research

November 17, 2011 Research and Development, Sales and Marketing EFPIA, Europe, IMI, antibiotic

The European Commission and the European pharma industry have unveiled plans to accelerate the discovery and development of new antibiotics. …

Jeremy Poland

November 17, 2011 Sales and Marketing MSI Consultancy

Pharmaceutical consultancy firm The MSI Consultancy has appointed Jeremy Poland as a Graduate Analyst in its Marketing Sciences division. Jeremy …

NICE will not back Eisai’s Halaven

November 17, 2011 Medical Communications, Sales and Marketing Eisai, Halaven, NICE, breast cancer

NICE has not recommended Eisai’s novel breast cancer drug Halaven due to concerns over its safety and cost.In draft guidance …

Life Healthcare makes four new appointments

November 16, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Life healthcare communications

Life Healthcare Communications has made four new appointments, adding to its client service, creative and digital teams. Vicki Marsh joins …

GSK diabetes drug fails head-to-head against Victoza

November 16, 2011 Sales and Marketing GLP-1, Victoza, albiglutide, diabetes

GlaxoSmithKline’s long-acting diabetes drug albiglutide has failed in a head-to-head trial against Novo Nordisk’s Victoza. Albiglutide is an injectable glucagon-like …
The Gateway to Local Adoption Series

Latest content